SABS · SAB Biotherapeutics, Inc.
$3.48
+0.03 (+0.87%)
At close · Jul 29
Market Cap
$266.10M
Shares
76.46M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| David Zaccardelli | Class II director | Appointed | 2026-01-07 |
| Rita Jain | Class II director | Appointed | 2026-01-07 |
| David Zaccardelli | Chairperson of the Board | Appointed | 2026-01-07 |